Journal of Mosquito Research, 2024, Vol.14, No.5, 264-275 http://emtoscipublisher.com/index.php/jmr 271 especially in regions with overlapping flavivirus transmission. This approach is particularly relevant for yellow fever-endemic areas where the population is also at risk for other flavivirus infections. One promising approach involves using virus replicon particles that can express antigens from multiple flaviviruses. For example, a study utilized a replicon system derived from Venezuelan equine encephalitis virus (VEEV) to express antigens from yellow fever and other flaviviruses, achieving cross-protective immune responses in animal models (Petrov et al., 2015). Another strategy involves chimeric constructs, where genetic elements of the yellow fever virus are combined with those of other flaviviruses to create a single vaccine that can induce immunity against multiple targets. The comparison of different immunization strategies demonstrated the IgG and neutralizing antibody (NtAb) responses to homologous and heterologous DENV serotypes following the use of the DENV-2 RD vaccine. The homologous DENV-2 antibody titers using the RD DNA-VLP combination were significantly higher than those of other combinations and also showed a significant advantage in cross-reactive IgG responses to DENV-3 (Figure 2) (Galula et al., 2018). This approach has been explored with chimeric yellow fever-dengue constructs, offering insights into the potential for broad-spectrum protection. Figure 2 DENV-specific antibody responses induced by CRR DENV-2 RD vaccine using various prime-boost immunization strategies (Adopted from Galula et al., 2018) The development of multivalent vaccines poses challenges, such as ensuring balanced immune responses to each component of the vaccine and avoiding the risk of antibody-dependent enhancement (ADE), a phenomenon where non-neutralizing antibodies enhance viral entry into host cells. Nevertheless, the potential to protect against multiple diseases with a single immunization makes multivalent vaccines a promising frontier in the fight against flavivirus-related diseases. 6 Future Directions and Research Priorities Yellow fever (YF) continues to pose a significant challenge to global health, despite the availability of a highly effective live-attenuated vaccine. Future efforts must focus on improving vaccine production and accessibility, enhancing vaccine safety through next-generation formulations, integrating vaccination with other control measures, and addressing vaccine hesitancy through effective public education and policy strategies. These priorities are essential to achieving the goals of the World Health Organization's Eliminate Yellow Fever Epidemics (EYE) initiative. 6.1 Strategies for improving vaccine production and accessibility The supply of yellow fever vaccines has historically struggled to meet global demand, especially during large outbreaks. One major issue is that the production process for the 17D vaccine relies on pathogen-free embryonated eggs, a method that is time-consuming and difficult to scale up rapidly during emergencies. Innovative approaches such as cell-culture-based production and the use of advanced bioreactor systems for Virus-Like Particle (VLP) production have shown promise in increasing scalability and reducing production time (Alvim et al., 2021).
RkJQdWJsaXNoZXIy MjQ4ODYzNA==